Rapport Therapeutics, Inc. Common Stock (RAPP) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Zero revenue ⢠Heavy investments RAPP has a very strong balance sheet and low leverage but no revenue, large operating losses, negative cash flow, and heavy investment spending that makes future value entirely contingent on investment outcomes and revenue generation.
Price Behavior
Key Price Behavior Insights: ⢠Below average ⢠Tight range ⢠Resistance rejection Support Level: $27.80â$28.00 Resistance Level: $30.50 RAPP is trading below its last month average (~$29.26) with short-term weakness, clear support near $27.80â$28.00 and repeated rejections around $30.50 that, if cleared with volume, would flip the bias bullish.
Sentiment & News
Key News Insights: ⢠Phase 3 Q2'26 ⢠China collaboration ⢠Strong cash runway Rapport Therapeutics reported robust RAPâ219 Phase 2a efficacy with a Phase 3 program slated for Q2 2026, expanded indications and longâacting work, a China licensing deal, strong cash runway (~$490.5M) and rising institutional supportâtogether signaling deârisking and upside into nearâterm catalysts.
AI Summary
RAPP has shifted from a binary research bet into a deârisked, multiâpath investmentâRAPâ219's Phaseâ2a signal, FDA acceptance for registrational trials and a Tenacia China deal backed by ~ $490M in liquid assets materially extend runway and reduce nearâterm dilution risk, but the thesis still pivots on one pivotal Phaseâ3 program and sustained burn so actively monitor Phaseâ3 enrollment/safety signals, Tenacia milestone receipts, and burn vs. announced runway as the key makeâorâbreak metrics.
Description
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its lead candidate, RAP-219, is a high-affinity inhibitor of TARPy8-containing AMPA receptors being evaluated for focal epilepsy and other CNS indications; the pipeline also includes an additional TARPy8 program and nicotinic acetylcholine receptor projects targeting chronic pain and hearing disorders. The company was incorporated in 2022, renamed from Precision Neuroscience NewCo in October 2022, and is based in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 15 | Sep 22 | RAPP | Rapport Therapeutics, Inc. Common Stock | Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term. | Closed | +5.6% |